# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mahalia Jackson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML035-SYN-TD
- Date: 1964-08-24
- Fictional facility: St. Posthumous Health Center
- Fictional author: Beatrice Fontenot, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month review with the repeat FDG-PET. **S**

## History of present illness

Ms. Jackson returns after about five and a half months of treatment. The repeat FDG-PET a week ago shows no remaining inflammation in the heart and much less in the lymph nodes, and the echocardiogram the same day shows an ejection fraction of 54 percent. She has taken prednisone 10 mg for three weeks and methotrexate 20 mg weekly. The laryngitis in June settled within ten days, and she has sung two concerts a week since late May without trouble. Her monthly methotrexate blood tests have been normal. The remote device checks show no ventricular tachycardia since March. She sleeps better on the lower dose and her appetite has settled. She would like to plan an autumn tour. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| FDG-PET and echocardiogram | No myocardial uptake; nodes smaller with low uptake; ejection fraction 54 percent from 47 |
| Treatment | Prednisone 10 mg; methotrexate 20 mg weekly |
| Device | No ventricular tachycardia since March; no shocks |
| Work | Two concerts a week since late May; autumn tour proposed |
| Laryngitis | Resolved within ten days |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight 93.0 kg; no fever |
| Respiratory | Negative | Breathless only on hills; no cough |
| Cardiovascular | Negative | No palpitations, shocks or fainting |
| Ears, nose, mouth, and throat | Negative | Voice back to normal; no mouth sores |
| Eyes | Negative | No redness or blurred vision |
| Psychiatric | Negative | Sleeping better; PHQ-9 4; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Prednisone 10 mg oral tablet, one tablet (10 mg) by mouth each morning **S**
- Methotrexate 2.5 mg oral tablet, eight tablets (20 mg) by mouth once a week on Sundays **S**
- Folic acid 1 mg oral tablet, one tablet by mouth daily **S**
- Alendronate 70 mg oral tablet, one tablet by mouth once weekly on rising, with a full glass of water, staying upright for 30 minutes **S**
- Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily **S**
- Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 130/82 mmHg; pulse 64 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 93 kg; BMI 32.2 kg/m². All vital signs are synthetic.

Hemoglobin: 13 g/dL; White cell count: 8.1 10*3/uL; Lymphocyte count: 1.4 10*3/uL; Platelets: 248 10*3/uL; Creatinine: 0.9 mg/dL; eGFR (CKD-EPI 1959): 77 mL/min/1.73 m²; Glucose: 108 mg/dL (high); Calcium: 9.5 mg/dL; ALT: 29 U/L; AST: 27 U/L; Alkaline phosphatase: 90 U/L; Albumin: 4.1 g/dL; Hemoglobin A1c: 6.2% (high); 25-hydroxyvitamin D: 34 ng/mL; NT-proBNP: 96 pg/mL; FVC percent predicted: 90%; FEV1 percent predicted: 89%; FEV1/FVC ratio: 79%; DLCO percent predicted: 76% (low); PHQ-9: 4. All results are synthetic.

## Change since baseline

- Hemoglobin: 12.4 g/dL at baseline, 13 g/dL at this visit **S**
- White cell count: 4.6 10*3/uL at baseline, 8.1 10*3/uL at this visit **S**
- Lymphocyte count: 0.9 10*3/uL (low) at baseline, 1.4 10*3/uL at this visit **S**
- Platelets: 232 10*3/uL at baseline, 248 10*3/uL at this visit **S**
- Creatinine: 1.08 mg/dL (high) at baseline, 0.9 mg/dL at this visit **S**
- eGFR (CKD-EPI 1959): 62 mL/min/1.73 m² at baseline, 77 mL/min/1.73 m² at this visit **S**
- Glucose: 104 mg/dL (high) at baseline, 108 mg/dL (high) at this visit **S**
- Calcium: 10.8 mg/dL (high) at baseline, 9.5 mg/dL at this visit **S**
- ALT: 28 U/L at baseline, 29 U/L at this visit **S**
- AST: 30 U/L at baseline, 27 U/L at this visit **S**
- Alkaline phosphatase: 128 U/L (high) at baseline, 90 U/L at this visit **S**
- Albumin: 4 g/dL at baseline, 4.1 g/dL at this visit **S**
- Hemoglobin A1c: 5.9% (high) at baseline, 6.2% (high) at this visit **S**
- 25-hydroxyvitamin D: 22 ng/mL (low) at baseline, 34 ng/mL at this visit **S**
- NT-proBNP: 210 pg/mL (high) at baseline, 96 pg/mL at this visit **S**

## Immunizations given today

- Recombinant zoster vaccine, dose 2 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 93.0 kg; blood pressure 130/82, pulse 64 and regular |
| Respiratory | Clear to auscultation |
| Cardiovascular | Regular rhythm; no murmur; device pocket normal |
| Mouth | No thrush or ulcers; voice clear |
| Skin | No rash, plaques or bruising |
| Psychiatric | Lively; planning her season |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Cardiac sarcoidosis in remission on treatment** (D86.85). Myocardial inflammation has resolved on PET and the ejection fraction has improved to 54 percent. Cardiac sarcoidosis can relapse as glucocorticoids are tapered, so methotrexate continues for at least a year and the taper is slow. The defibrillator stays: the scar remains and the risk of ventricular tachycardia is lower but not gone. **S**
   - Prednisone 10 mg until late September, then 7.5 mg, and 5 mg from November if well.
   - Methotrexate 20 mg weekly for at least a year in all.
   - Repeat FDG-PET about three months after reaching 5 mg, or sooner for palpitations or shocks.
   - Clinic device check this month; remote checks monthly.
2. **Pulmonary sarcoidosis** (D86.2). Lung function further improved: FVC 90 percent and DLCO 76 percent of predicted. **S**
   - Lung function every three to six months while the treatment changes.
3. **Long-term systemic glucocorticoid treatment** (Z79.52). Blood pressure 130/82, glucose 108 mg/dL and A1c 6.2%, weight down 1 kg as the dose falls. Calcium 9.5 mg/dL and 25-hydroxyvitamin D 34 ng/mL on 1000 units daily. Atovaquone was stopped in July when prednisone fell below 20 mg. **S**
   - Second recombinant zoster dose today.
   - Continue alendronate and cholecalciferol.
   - Eye examination with pressure check in March, one year after the first.
4. **Acute viral laryngitis** (J04.0). Resolved within ten days without antibiotics. **S**
   - Problem resolved.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Cardiac FDG-PET | Three to six months into treatment, and after major dose changes | Up to date | A week ago: no myocardial uptake; nodes smaller with low uptake |
| Imaging | Echocardiogram | With the repeat PET, and for symptoms | Up to date | A week ago: ejection fraction 54 percent |
| Imaging | Spirometry and diffusing capacity (FVC, FEV1, FEV1/FVC, DLCO) | At diagnosis, three months after starting treatment, then every three to six months while treatment changes | Completed today | FVC 90 percent, FEV1 89 percent, FEV1/FVC 79 percent, DLCO 76 percent of predicted |
| Laboratory | Methotrexate safety: blood count, liver tests and creatinine | Before starting; every two to four weeks for the first three months; then every eight to twelve weeks | Completed today | Hemoglobin 13.0 g/dL, white cells 8.1, lymphocytes 1.4, platelets 248; ALT 29, AST 27, alkaline phosphatase 90 U/L, albumin 4.1 g/dL; creatinine 0.90 mg/dL, eGFR 77; the monthly tests since May were normal; now every eight to twelve weeks |
| Laboratory | Serum calcium | At diagnosis, then at each treatment visit while it was raised or vitamin D is given | Completed today | 9.5 mg/dL on cholecalciferol |
| Laboratory | 25-hydroxyvitamin D | After replacement starts | Completed today | 34 ng/mL |
| Laboratory | Glucose and A1c on glucocorticoids | At each visit; A1c every three months | Completed today | Glucose 108 mg/dL; A1c 6.2% |
| Laboratory | NT-proBNP | At each cardiac review | Completed today | 96 pg/mL, normal |
| Examination | Defibrillator check (remote and in clinic) | Remote transmissions monthly and with any symptom; clinic check every three to six months | Completed today | Remote transmissions monthly: no ventricular tachycardia since March; clinic check booked this month |
| Examination | Eye examination | Yearly with sarcoidosis and on glucocorticoids | Up to date | Normal in March; next due in March |
| Imaging | Bone density (DXA) | Every one to three years on glucocorticoids | Up to date | March; repeat in two years |
| Medication safety | Pneumocystis prophylaxis | While prednisone is 20 mg or more with a second immunosuppressant | Not indicated | Stopped in July when prednisone fell below 20 mg |
| Medication safety | Vaccination on immunosuppression | Per schedule | Completed today | Recombinant zoster dose 2 given today; influenza and COVID-19 due in the autumn |
| Survey | Depression screen (PHQ-9) | At diagnosis and at each phase of treatment | Completed today | PHQ-9 4 |
| Self-management | Performing and travel plan | At each visit | Completed today | Autumn tour in the United States approved with rest days and the same medicine and device plan; a tour abroad next spring to be decided after the next review |

## Goal progress

- Tissue diagnosis with other causes excluded, and screening of the eyes, heart, calcium, liver and kidneys, within four weeks of presentation. Outcome by 1964-03-09: EBUS in nine days; eye examination, Holter, echocardiogram, cardiac MRI and FDG-PET within four weeks. **S**
- Calcium in the normal range within three months. Outcome by 1964-05-11: Calcium 9.6 mg/dL after nine weeks of treatment. **S**
- FVC and DLCO improved by at least 10 percent of predicted within six months. Outcome by 1964-08-24: FVC 74 to 90 percent and DLCO 62 to 76 percent of predicted. **S**
- No myocardial FDG uptake on repeat PET after about six months of treatment, with left ventricular function stable or better. Outcome by 1964-08-24: Myocardial uptake resolved; ejection fraction 54 percent from 47. **S**
- Prednisone at 10 mg a day or less by six months, with methotrexate as the steroid-sparing agent. Outcome by 1964-08-24: Prednisone 10 mg at six months and tapering. **S**
- Back on stage with a schedule she can sustain, with her voice protected. Outcome by 1964-08-24: Two concerts a week since late spring; a longer autumn tour planned. **S**

## Guideline basis

- Crouser ED, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020;201(8):e26-e51 (PMID 32293205) (2020), American Thoracic Society
- Baughman RP, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021;58(6):2004079 (PMID 34140301) (2021), European Respiratory Society
- Birnie DH, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11(7):1305-1323 (PMID 24819193) (2014), Heart Rhythm Society
- Cheng RK, et al. Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association. Circulation 2024;149(21):e1197-e1216 (PMID 38634276) (2024), American Heart Association
- Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (PMID 37845798) (2022), American College of Rheumatology
- Singh JA, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64(5):625-639 (PMID 22473917) (methotrexate laboratory monitoring) (2012), American College of Rheumatology
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Clinic device check this month. Methotrexate blood tests every eight to twelve weeks. Preventive visit in about six weeks with influenza and COVID-19 vaccines. Pulmonology review in three months. **S**
- Next scheduled visit 1964-10-05: periodic adult preventive visit. **S**
